The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 24, 2025
Filed:
Jun. 22, 2023
Applicant:
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Inventors:
Wayne A. Marasco, Wellesley, MA (US);
Quan Zhu, Southborough, MA (US);
De-Kuan Chang, Boston, MA (US);
Assignee:
Dana-Farber Cancer Institute, Inc., Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 40/11 (2025.01); A61K 39/395 (2006.01); A61K 40/42 (2025.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 40/11 (2025.01); A61K 40/428 (2025.01); C07K 16/18 (2013.01); C07K 16/24 (2013.01); C07K 16/246 (2013.01); C07K 16/2809 (2013.01); C07K 16/2866 (2013.01); A61K 2039/507 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/59 (2023.05); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2319/01 (2013.01);
Abstract
The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.